What's in Australasian Gastro-Intestinal Trials Group's pipeline?

Australasian Gastro-Intestinal Trials Group has 8 drugs in our index: 0 marketed, 0 filed, 2 in Phase 3, 6 in Phase 2, 0 in Phase 1.

Which companies overlap with Australasian Gastro-Intestinal Trials Group's portfolio?

Top competitors by shared drug class: Ain Shams University, Arbutus Biopharma Corporation, Casa Sollievo della Sofferenza IRCCS, Centre Oscar Lambret, Chinese PLA General Hospital.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/australasian-gastro-intestinal-trials-group.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Australasian Gastro-Intestinal Trials Group — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Australasian Gastro-Intestinal Trials Group pipeline: 0 marketed, 0 filed, 2 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 6 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Trifluridine/Tipracil	Trifluridine/Tipracil	phase 3	Antiviral	Thymidylate synthase, Dihydrofolate reductase	Oncology
Pegylated G-CSF	Pegylated G-CSF	phase 3	Growth factor	G-CSF receptor	Oncology

Therapeutic area mix

Oncology · 2
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Ain Shams University · 1 shared drug class
Arbutus Biopharma Corporation · 1 shared drug class
Casa Sollievo della Sofferenza IRCCS · 1 shared drug class
Centre Oscar Lambret · 1 shared drug class
Chinese PLA General Hospital · 1 shared drug class
Genzyme, a Sanofi Company · 1 shared drug class
Hospital Universitari Vall d'Hebron Research Institute · 1 shared drug class
Adocia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Australasian Gastro-Intestinal Trials Group:

Cite this brief

Drug Landscape (2026). Australasian Gastro-Intestinal Trials Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/australasian-gastro-intestinal-trials-group. Accessed 2026-05-16.